Compare Invesco WilderHill Clean Energy ETF (PBW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Invesco WilderHill Clean Energy ETF trades at $25.75 (market cap $315.85M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 23.8× Invesco WilderHill Clean Energy ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco WilderHill Clean Energy ETF for 47 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PBW | SYRE | |
|---|---|---|
Market Cap | $315.85M | $7.52B |
Volume | 452,833 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $108.92 |
52-Week Low | $25.77 | $22.18 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Invesco WilderHill Clean Energy ETF (PBW) trades at $27.33, down 0.33% on the day, with a bearish technical signal driven by moving averages. Key financial ratios such as P/E and P/S are not applicable for this ETF. Recent news highlights institutional selling, with IFP Advisors cutting its stake by 96.3% in Q2 2026 (SEC filing, September 18, 2026).
The outlook is cautious due to technical weakness and institutional outflows. Opportunities lie in the clean energy theme amid global investment, but risks include high volatility and concentrated portfolio strategy. The ETF's performance is tied to sector sentiment rather than traditional corporate fundamentals.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
